Nyon, Switzerland (ots/PRNewswire) - New campaign, Let's treat it right, launches as online searches for self-care surge globally[1], as people take more responsibility for their everyday health. Today sees the launch of Let's treat it right, a major new health education campaign designed to bridge a knowledge gap ...
Barcelona, Spain and Copenhagen, Denmark (ots/PRNewswire) - - The successful completion of a decentralized procedure is the final step before national marketing authorizations can be granted by the European countries - MC2 Therapeutics has granted Almirall exclusive European rights to commercialize this topical ...
Copenhagen (ots/PRNewswire) - Valcon Medical A/S ("Valcon Medical" or the "Company"), Denmark's leading independent cannabis concentrate and medical formulation provider, received its licensing for the commercial production of cannabis from the Danish Medicines Agency (DKMA) earlier in May 2021. Under the DKMA ...
Amsterdam (ots/PRNewswire) - NORGINE B.V. (Norgine) a leading European specialist pharmaceutical company and Beijing Podconley Pharmaceutical Technology & Development Co., Ltd. (Beijing Podconley), today announced an exclusive distribution agreement by which Beijing Podconley will commercialise Norgine's product ...
Lausanne, Switzerland, Seoul, Republic of Korea (ots) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company and Ubix Therapeutics (en.ubixtrx.com), a South Korea-based biotech company today announced their co-research agreement combining two novel proprietary technologies to specifically ...
Lausanne, Switzerland (ots) - - Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of Non-Hodgkin’s Lymphoma (NHL), representing 30-40% of cases. Nearly half of DLBCL patients are not cured by first-line treatment, leaving a large number of patients at risk of worsening disease1 - Naratuximab ...
London and Toronto (ots/PRNewswire) - Apollon Formularies plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION) ("Aion"), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that joint ...
Darmstadt, Germany (ots/PRNewswire) - - Merck to support up to six additional research projects at the BioMed X Institute in Heidelberg within the next six years - Call for application for a global crowdsourcing project, 'Regulatory T Cell Dysfunction in Autoimmunity and Inflammaging' Merck, a leading science and ...
London (ots/PRNewswire) - Materia, a medical cannabis and wellness company focused on the European market, today announces that its wholly-owned subsidiary Materia Malta Operating Ltd. ("Materia Malta" or the "Company") has received its European Union Good Manufacturing Practices ("EU GMP") certification from the Malta Medicines Authority. EU GMP is the global gold standard for pharmaceutical production and a requirement ...
Toronto (ots/PRNewswire) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the "Aion Mushroom Preparations" or "Preparations") showed high efficacy in killing HER2+ breast ...
Ness-Ziona, Israel (ots/PRNewswire) - Vidac Pharma LTD (Vidac) a clinical-stage Israel biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS ("GEM") a Luxemburg-based private alternative investment group for a EUR 20 million capital commitment. Under the agreement, GEM commits to provide Vidac with a share subscription facility of up to EUR 20 million for a 36-month term ...
Schweizerischer Nationalfonds / Fonds national suisse
Bern (ots) - Most antibiotics need to penetrate their target bacteria. But Darobactin, a newly discovered compound, is much too large to do so. Nonetheless, it kills many antibiotic-resistant pathogens - by exploiting a tiny weak spot on their surface. Basel researchers have now revealed the amazing mechanism at play and thereby opened the door to developing completely new medicines. An increasing number of bacterial ...
Prague (ots/PRNewswire) - Zentiva and mAbxience announce their collaboration for the launch of the ALYMSYS® (bevacizumab) following its European Marketing Authorisation on March 26th. The EC approval is based on a comprehensive clinical and scientific package which demonstrated biosimilarity of ALYMSYS® to the ...
Willington, England (ots/PRNewswire) - Bionical Emas, a global specialist Clinical Research Organization (CRO) has today announced the launch of a Managed Access Program for Jazz Pharmaceuticals' medicinal product JZP-458 for the treatment of patients with Acute Lymphoblastic Leukaemia (ALL) and Lymphoblastic ...
Duesseldorf, Germany (ots/PRNewswire) - - Organic revenue growth of 3.1 % in core business - Strong development in High Value Solutions: Focus on Biological Solutions pays off - Adjusted EBITDA increases organically by 7.0 % in core business - Adjusted earnings per share rise organically by 29.3 % to EUR 0.57 - Guidance confirmed for the financial year 2021 "We got off to a good start in the financial year," said Dietmar ...
Cologne (ots) - 30-year pharma veteran Rolf Hoffmann, formerly senior global executive at Amgen and Eli Lilly, joins Semdor Pharma as investor and commercial expert. Semdor Pharma Group announced today that it has added Rolf Hoffmann, a seasoned global pharma executive and advisor, to its Board of Directors, as well as an investor in the company. Mr. Hoffmann ...
Cork, Ireland (ots/PRNewswire) - Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its Phase 2 clinical trial in 270 patients with Dry Eye caused by Meibomian Gland Dysfunction (MGD). The well controlled and representative study was conducted across 26 ...
Toronto (ots/PRNewswire) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms. The patent applications include use of medicinal mushrooms for the treatment of human cancers including breast cancer, use of combination medical ...
Brussels and Atlanta (ots/PRNewswire) - - Through this collaboration with Microsoft, UCB seeks to discover and develop medicines faster for people living with severe diseases in immunology and neurology - Microsoft will provide AI technology and applied scientists to work alongside UCB's scientists and data specialists, aiming to allow UCB to discover new correlations ...
Stans, Switzerland (ots) - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces the pricing of its initial public offering of 4,819,277 units at a price of ...
Tel Aviv, Israel / Lausanne, Switzerland (ots) - Nucleai (www.Nucleaimd.com), a global provider in pathology-based biomarker discovery, and Debiopharm (www.debiopharm.com), a Swiss-based biopharmaceutical company specializing in drug development, announced that they have entered into a long-term collaboration to ...
Lisbon, Portugal (ots/PRNewswire) - Hovione, the leader in Pharmaceutical Spray Drying, today announced the launch of ASD-HIPROS, a proprietary screening service for spray dried dispersions. This platform is the most advanced and most accurate tool to identify optimal and commercially viable Amorphous Solid ...
Paris and Boston (ots/PRNewswire) - - Transaction includes commercial, clinical and research-stage oncology portfolio and employees for up to $2 billion plus royalties - Includes Agios' marketed medicine TIBSOVO® and a strong oncology pipeline of Phase 3 and early-stage assets - Acquisition in-line with Servier's strategic ambition to become a recognized and innovative player in oncology, supported by unique drug ...
Heidelberg, Germany (ots/PRNewswire) - - ESSENCE-2 is the second registration trial to complete the clinical development of CyclASol® as agreed with U.S. Food and Drug Administration (FDA) - Designed to replicate efficacy demonstrated in previous phase 2/3 ESSENCE-1 trial - Topline data expected in 2nd half 2021 ...
SIFI Press & Communication Office
Catania, Italy (ots/PRNewswire) - Given urgency to treat, SIFI has established a dedicated cross-functional team to accelerate the launch of polihexanide monotherapy in Europe and the United States. SIFI, a leading ophthalmic company, is pleased to announce the recent appointment of Jelle Kleijn, PhD, as Global Head ...
BD (Becton, Dickinson and Company)
Franklin Lakes, N.j. (ots/PRNewswire) - - Investment includes new manufacturing facility in Europe BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to invest approximately $1.2 billion over a 4-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and ...
Amsterdam, The Netherlands (ots/PRNewswire) - Norgine B.V. ("Norgine"), today announced the establishment of a wholly-owned subsidiary, Norgine Healthcare B.V. ("Norgine Healthcare"), which will be dedicated to consumer healthcare. To view the Multimedia News Release, please click: ...
Zurich (ots) - In 2019, medication costs in Switzerland totalled approximately CHF 7.6 billion. The front runners remained cancer and immune system drugs, followed by nervous system medications and metabolic preparations. The use of biosimilars (generic preparations) offers significant savings potential that unfortunately remains almost completely unexploited. In an ...
Fresenius Kabi Deutschland GmbH
BAD HOMBURG (ots) - Evidence indicates that omega-3 (?-3) fatty acid containing parenteral nutrition (PN) improves clinical outcomes compared with standard PN in adult patients,1 underlining its role in today's hospitals and clinics. To support continuous health care professional (HCP) education on omega-3 fatty ...
Dublin (ots/PRNewswire) - GH Research Limited ("GH Research" or "the Company") today announced the successful completion of a Phase 1 clinical study with GH001 in healthy volunteers. The Company is currently recruiting for a Phase 1/2 clinical study with GH001 in patients with Treatment-Resistant Depression. GH ...